431 related articles for article (PubMed ID: 28801849)
1. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
Rosen LS; Jacobs IA; Burkes RL
Target Oncol; 2017 Oct; 12(5):599-610. PubMed ID: 28801849
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
3. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
Melosky B; Reardon DA; Nixon AB; Subramanian J; Bair AH; Jacobs I
Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
Rhodes W; DeClue RW; Accortt NA; Jin R; Sandschafer D; Wertz D; Patel K
Future Oncol; 2021 Dec; 17(36):5119-5127. PubMed ID: 34698523
[No Abstract] [Full Text] [Related]
6. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
[TBL] [Abstract][Full Text] [Related]
8. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer.
Pham C; Niu F; Delate T; Buchschacher GL; Li Y; Ekinci E; Le K; Hui RL
BioDrugs; 2023 Nov; 37(6):891-899. PubMed ID: 37747629
[TBL] [Abstract][Full Text] [Related]
9. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
[TBL] [Abstract][Full Text] [Related]
10. [The development of biosimilars in oncology].
Jiang SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
[TBL] [Abstract][Full Text] [Related]
11. A Prospective, Randomized, Multiple-Dose, Multi-Center, Comparative Clinical Study to Evaluate the Efficacy, Safety, Immunogenicity of a biosimilar Bevacizumab (Test product, Hetero) and Reference Medicinal Product (Bevacizumab, Roche) in Patients of Metastatic Colorectal Cancer.
Advani S; Biswas G; Sinha S; B B; Bandi VK; Naidu N; Thakur P; Chary S
J Assoc Physicians India; 2018 Jun; 66(6):55-59. PubMed ID: 31331137
[TBL] [Abstract][Full Text] [Related]
12. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
13. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
14. Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice.
Yang J; Kelton JM; Thompson J; Alvir JMJ; Maculaitis MC; Shelbaya A
Am J Manag Care; 2022 Apr; 28(4):160-166. PubMed ID: 35420744
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab treatment in metastatic colorectal carcinoma - an economic perspective.
Sehnalová I; Říhová B; Demlová R
Ceska Slov Farm; 2019; 68(2):43-47. PubMed ID: 31331174
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta-analysis in anorectal medicine.
Li Y; Mei Z; Shi L; Wan Y; Zhou X; Zeng T; Liu Y; Yang JY; Shi Z
Int Wound J; 2024 Jan; 21(1):e14638. PubMed ID: 38272807
[TBL] [Abstract][Full Text] [Related]
17. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
18. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
20. Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.
Ito M; Kusaba H; Mukaide S; Kishimoto J; Shimokawa H; Tamura S; Makiyama A; Hirano G; Oda H; Shirakawa T; Komoda M; Uchino K; Tanaka R; Mitsugi K; Esaki T; Arita S; Ariyama H; Akashi K; Baba E
Anticancer Drugs; 2017 Nov; 28(10):1166-1173. PubMed ID: 28906258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
